Image for representational purpose only. (Photo | AP) 
India

SII applies for full market authorisation of Covishield as supplies of vaccine exceeded 125 crore doses

SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the Indian government

PTI

NEW DELHI: Serum Institute of India (SII) CEO Adar Poonawala on Friday said it has applied to Indian authorities for full market authorisation of Covishield, stating supplies of the COVID-19 vaccine have exceeded 125 crore doses.

SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the Indian government, which had in January this year granted emergency use authorisation in the country.

"Supplies of the COVISHIELD vaccine in India, have exceeded 1.25 billion doses. The government of India now has enough data for full market authorisation, and therefore @SerumInstIndia has applied to the @CDSCO_INDIA_INF (DCGI) and @MoHFW_INDIA for this permission," Poonawala said in a tweet tagging the Central Drugs Standard Control Organisation (CDSCO) and Ministry of Health and Family Welfare.

Trump slams US Supreme Court ruling on birthright citizenship; calls it 'too bad for country'

PM Modi talks to Iran's President Pezeshkian; backs dialogue, diplomacy in West Asia

An “ocean of opportunity” and of competition

India-Japan annual summit to focus on AI, mobility roadmap and maritime cooperation

Atleast 14 children killed as roof of tutoring centre collapse in eastern Pakistan

SCROLL FOR NEXT